Overview

A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.
Phase:
Phase 2
Details
Lead Sponsor:
Tony Bekaii-Saab
Collaborator:
Roche Pharma AG
Treatments:
Capecitabine
Docetaxel